(NASDAQ: IBIO) Ibio's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 12%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 36.33%.
Ibio's earnings in 2026 is -$24,737,000.On average, 7 Wall Street analysts forecast IBIO's earnings for 2026 to be -$10,756,865, with the lowest IBIO earnings forecast at -$11,848,441, and the highest IBIO earnings forecast at -$8,342,270. On average, 6 Wall Street analysts forecast IBIO's earnings for 2027 to be -$10,463,245, with the lowest IBIO earnings forecast at -$13,202,549, and the highest IBIO earnings forecast at -$6,818,899.
In 2028, IBIO is forecast to generate -$15,309,706 in earnings, with the lowest earnings forecast at -$22,004,248 and the highest earnings forecast at -$7,945,019.